An Observational Study of the Safety of Atezolizumab in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer in Argentina
Latest Information Update: 15 Mar 2023
Price :
$35 *
At a glance
- Drugs Atezolizumab (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Roche
- 09 Mar 2023 Status changed from not yet recruiting to completed.
- 11 Dec 2017 Planned initiation date changed from 20 Nov 2017 to 11 Dec 2017.
- 01 Nov 2017 New trial record